Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Sees Large Decrease in Short Interest

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) saw a large decline in short interest in September. As of September 30th, there was short interest totaling 1,012 shares, a decline of 80.8% from the September 15th total of 5,259 shares. Based on an average daily volume of 31,252 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the shares of the stock are sold short.

Cardio Diagnostics Stock Down 4.8%

CDIO traded down $0.09 during trading on Monday, hitting $1.78. The company had a trading volume of 61,445 shares, compared to its average volume of 1,313,264. The company has a market capitalization of $5.27 million, a PE ratio of -0.61 and a beta of 2.29. The firm’s 50-day moving average price is $1.92 and its 200 day moving average price is $1.88. Cardio Diagnostics has a one year low of $0.97 and a one year high of $7.91.

Cardio Diagnostics (NASDAQ:CDIO) last announced its earnings results on Friday, August 7th. The company reported ($0.51) EPS for the quarter. The business had revenue of $0.01 million for the quarter. Cardio Diagnostics had a negative return on equity of 82.28% and a negative net margin of 43,133.33%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cardio Diagnostics stock. Renaissance Technologies LLC acquired a new stake in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,348 shares of the company’s stock, valued at approximately $30,000. Renaissance Technologies LLC owned 0.52% of Cardio Diagnostics at the end of the most recent reporting period. 8.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cardio Diagnostics in a research note on Tuesday, September 8th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Cardio Diagnostics currently has an average rating of “Sell”.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc is a biotechnology company focused on developing precision medicine solutions for the prevention, detection and management of cardiovascular disease. The company combines genetic, epigenetic and clinical data with artificial intelligence to create blood-based tools designed to help identify an individual’s risk of coronary heart disease and support personalized care.

Its product portfolio has included Epi+Gen CHD, a blood-based test intended to assess a person’s susceptibility to coronary heart disease and provide information that may support preventive interventions.